Aliases & Classifications for Aphasia

MalaCards integrated aliases for Aphasia:

Name: Aphasia 12 54 29 55 6 43 15 73


External Ids:

Disease Ontology 12 DOID:0060046
UMLS 73 C0003537

Summaries for Aphasia

NINDS : 54 Aphasia is a neurological disorder caused by damage to the portions of the brain that are responsible for language production or processing.  It may occur suddenly or progressively, depending on the type and location of brain tissue involved.  Primary signs of the disorder include difficulty in expressing oneself when speaking, trouble understanding speech, and difficulty with reading and writing. Aphasia is not a disease, but a symptom of brain damage. Although it is primarily seen in individuals who have suffered a stroke, aphasia can also result from a brain tumor, infection, inflammation, head injury, or dementia that affect language-associated regions of the brain. It is estimated that about 1 million people in the United States today suffer from aphasia. The type and severity of language dysfunction depends on the precise location and extent of the damaged brain tissue. Generally, aphasia can be divided into four broad categories: (1) Expressive aphasia (also called Broca's aphasia) involves difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. (2) Receptive aphasia (Wernicke's aphasia) involves difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. (3) Global aphasia results from severe and extensive damage to the language areas of the brain.  People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write.  (4) Indiivfduals with anomic or amnesia aphasia, the least severe form of aphasia, have difficulty in using the correct names for particular objects, people, places, or events.

MalaCards based summary : Aphasia is related to frontotemporal lobar degeneration with tdp43 inclusions, grn-related and nominal aphasia, and has symptoms including back pain, cachexia and cyanosis. An important gene associated with Aphasia is L1CAM (L1 Cell Adhesion Molecule), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Neuroscience. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cellular

MedlinePlus : 43 Aphasia is a disorder caused by damage to the parts of the brain that control language. It can make it hard for you to read, write, and say what you mean to say. It is most common in adults who have had a stroke. Brain tumors, infections, injuries, and dementia can also cause it. The type of problem you have and how bad it is depends on which part of your brain is damaged and how much damage there is. There are four main types: Expressive aphasia - you know what you want to say, but you have trouble saying or writing what you mean Receptive aphasia - you hear the voice or see the print, but you can't make sense of the words Anomic aphasia - you have trouble using the correct word for objects, places, or events Global aphasia - you can't speak, understand speech, read, or write Some people recover from aphasia without treatment. Most, however, need language therapy as soon as possible. NIH: National Institute of Neurological Disorders and Stroke

Disease Ontology : 12 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language.

Wikipedia : 76 Aphasia is an inability to comprehend and formulate language because of damage to specific brain... more...

Related Diseases for Aphasia

Diseases related to Aphasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 34.4 GRN MAPT
2 nominal aphasia 32.8 C9orf72 CHMP2B GRN MAPT PSEN1
3 progressive non-fluent aphasia 32.8 C9orf72 CHMP2B GRN MAPT PSEN1
4 agraphia 31.8 GRN MAPT PRNP PSEN1
5 semantic dementia 31.5 APOE C9orf72 CHMP2B GRN MAPT PSEN1
6 alexia 31.0 APOE PSEN1
7 apraxia 30.7 C9orf72 FOXP2 GRN MAPT PSEN1
8 associative agnosia 30.7 GRN PSEN1
9 ideomotor apraxia 30.5 GRN MAPT PSEN1
10 creutzfeldt-jakob disease 30.5 APOE MAPT PRNP
11 mutism 30.5 CHMP2B GRN
12 posterior cortical atrophy 30.4 APOE MAPT
13 akinetic mutism 30.4 MAPT PRNP
14 echolalia 30.2 GRN MAPT PSEN1
15 visual agnosia 30.1 GRN PSEN1
16 pick disease of brain 30.0 APOE APP GRN MAPT PSEN1 SNCA
17 prion disease 29.9 APP MAPT PRNP
18 kluver-bucy syndrome 29.7 APP MAPT PSEN1
19 speech disorder 29.5 FOXP2 GRIN2A GRN
20 reading disorder 29.0 FOXP2 PSEN1
21 behavioral variant of frontotemporal dementia 28.6 C9orf72 CHMP2B GRN MAPT PSEN1
22 motor neuron disease 28.4 C9orf72 GRN MAPT SNCA
23 supranuclear palsy, progressive, 1 27.7 APOE APP C9orf72 GRN LRRK2 MAPT
24 alzheimer disease 27.2 APOE APP GRIN2A GRN MAPT PRNP
25 frontotemporal dementia 27.2 APOE APP C9orf72 CHMP2B GRN LRRK2
26 amyotrophic lateral sclerosis 1 26.4 APP C9orf72 CHMP2B GRN MAPT PRNP
27 dementia 25.7 APOE APP C9orf72 CHMP2B GRN LRRK2
28 epilepsy-aphasia spectrum 12.4
29 logopenic progressive aphasia 12.4
30 landau-kleffner syndrome 11.9
31 epilepsy, focal, with speech disorder and with or without mental retardation 11.9
32 progressive supranuclear palsy-progressive non-fluent aphasia syndrome 11.8
33 intellectual disability-expressive aphasia-facial dysmorphism syndrome 11.8
34 masa syndrome 11.7
35 gerstmann syndrome 11.6
36 spastic paraplegia 1 11.4
37 cerebral atrophy 11.4
38 moyamoya disease 1 11.1
39 marchiafava bignami disease 11.1
40 autosomal dominant partial epilepsy with auditory features 10.9
41 sudanophilic cerebral sclerosis 10.8
42 frontotemporal dementia, chromosome 3-linked 10.8
43 progressive multifocal leukoencephalopathy 10.8
44 handl syndrome 10.8
45 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 10.8
46 x-linked charcot-marie-tooth disease 10.8
47 myelinoclastic diffuse sclerosis 10.8
48 simultanagnosia 10.7 APOE MAPT
49 genetic prion diseases 10.7 APOE PRNP
50 phonagnosia 10.6 GRN PSEN1

Graphical network of the top 20 diseases related to Aphasia:

Diseases related to Aphasia

Symptoms & Phenotypes for Aphasia

UMLS symptoms related to Aphasia:

back pain, cachexia, cyanosis, dyspnea, edema, fever, headache, icterus, other symptoms involving head and neck, pain, sciatica, seizures, signs and symptoms, signs and symptoms, digestive, syncope, tremor, vertigo, chronic pain, swelling, mass, or lump in head and neck, aprosodia, aphasic, sore throat, scanning speech, symptoms involving head and neck, other and unspecified speech disturbances, other symbolic dysfunction, vertigo/dizziness, hot flushes, sleeplessness, other speech disturbances, central nervous system signs and symptoms

MGI Mouse Phenotypes related to Aphasia:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 GRN APP L1CAM C9orf72 APOE GRIN2A
2 cellular MP:0005384 10.22 GRN APP L1CAM C9orf72 APOE PSEN1
3 nervous system MP:0003631 10.22 GRN APP L1CAM C9orf72 APOE CHMP2B
4 immune system MP:0005387 10.18 GRN APP C9orf72 APOE PSEN1 MAPT
5 mortality/aging MP:0010768 10.17 GRN APP L1CAM C9orf72 APOE PSEN1
6 growth/size/body region MP:0005378 10.16 APOE APP L1CAM C9orf72 PSEN1 MAPT
7 hematopoietic system MP:0005397 10.15 APOE GRN APP C9orf72 LRRK2 PSEN1
8 integument MP:0010771 10.11 APP L1CAM APOE GRIN2A PSEN1 MAPT
9 no phenotypic analysis MP:0003012 10.02 GRN APP L1CAM C9orf72 APOE MAPT
10 reproductive system MP:0005389 9.8 APOE GRN APP L1CAM PSEN1 PRNP
11 skeleton MP:0005390 9.7 APOE L1CAM LRRK2 PSEN1 SLC20A2 PRNP
12 pigmentation MP:0001186 9.62 APOE GRN LRRK2 L1CAM
13 vision/eye MP:0005391 9.17 APOE GRN L1CAM PSEN1 MAPT SLC20A2
14 taste/olfaction MP:0005394 9.13 APOE MAPT SNCA

Drugs & Therapeutics for Aphasia

Drugs for Aphasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
Donepezil Approved Phase 4 120014-06-4 3152
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
6 Piracetam Approved, Investigational Phase 4,Phase 1 7491-74-9
Levodopa Approved Phase 4,Phase 2,Phase 3,Not Applicable 59-92-7 6047
Citalopram Approved Phase 4 59729-33-8 2771
Testosterone Approved, Investigational Phase 4 58-22-0 6013
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Amantadine Approved Phase 4,Phase 2,Phase 3 768-94-5 2130
12 tannic acid Approved, Nutraceutical Phase 4,Phase 3
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
14 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
17 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Cholinergic Agents Phase 4,Phase 2,Not Applicable
20 Cholinesterase Inhibitors Phase 4,Phase 2,Not Applicable
21 Nootropic Agents Phase 4,Phase 2,Phase 1,Not Applicable
22 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Not Applicable
26 Analgesics Phase 4,Phase 3,Phase 2
27 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
28 Anti-Inflammatory Agents Phase 4,Phase 3
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
30 Antipyretics Phase 4,Phase 3
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2
32 Cyclooxygenase Inhibitors Phase 4,Phase 3
33 Fibrinolytic Agents Phase 4,Phase 3
34 Platelet Aggregation Inhibitors Phase 4,Phase 3,Not Applicable
35 Dopamine agonists Phase 4,Not Applicable
36 Antidepressive Agents Phase 4,Phase 2,Phase 1,Not Applicable
37 Antidepressive Agents, Second-Generation Phase 4,Not Applicable
38 Psychotropic Drugs Phase 4,Phase 2,Phase 1,Not Applicable
39 Serotonin Agents Phase 4,Not Applicable
40 Serotonin Uptake Inhibitors Phase 4,Not Applicable
41 Androgens Phase 4
42 Hormone Antagonists Phase 4,Phase 3
43 Hormones Phase 4,Phase 3
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
45 Antipsychotic Agents Phase 4
46 Central Nervous System Depressants Phase 4,Phase 2,Phase 1,Not Applicable
47 Dopamine Antagonists Phase 4
48 Serotonin Antagonists Phase 4
49 Tranquilizing Agents Phase 4,Phase 2,Phase 1
50 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 330)
# Name Status NCT ID Phase Drugs
1 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
2 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
3 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
4 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
5 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4 levodopa
6 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
7 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
8 Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke Completed NCT01762163 Phase 4 Qizhitongluo Capsule;Naoxintong Capsule;Aspirin Enteric-coated Tablets;placebo
9 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
10 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
11 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
12 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
13 A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke Terminated NCT01883011 Phase 4 Piracetam
14 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
15 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Unknown status NCT02241213 Phase 3
16 Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation Unknown status NCT00822068 Phase 2, Phase 3
17 Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI) Unknown status NCT02817789 Phase 3 Ticagrelor alone;Combination lysine acetylsalicylate - clopidogrel
18 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
19 Action of Amantadine on Post-Stroke Aphasic Patients Completed NCT00821691 Phase 2, Phase 3 Amantadin;Placebo
20 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer Completed NCT00390806 Phase 3 HYCAMTIN, oral capsules
21 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
22 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
23 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
24 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
25 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
26 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes Recruiting NCT02618577 Phase 3 Edoxaban;ASA
27 iMRI Guided Resection in Cerebral Glioma Surgery Recruiting NCT01479686 Phase 3
28 Use of Local Intraoperative Steroid in MIS TLIF Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
29 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
30 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
31 Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage. Not yet recruiting NCT03187405 Phase 3 EVD + IVF with Alteplase
32 Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia Terminated NCT01277575 Phase 3
33 Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4) Terminated NCT00856661 Phase 3 Desmoteplase;Placebo
34 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 TRx0237
35 Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study Unknown status NCT02540109 Phase 2
36 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
37 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation Unknown status NCT01221779 Phase 2
38 Dextroamphetamine and tDCS to Improve the Fluency Unknown status NCT02514044 Phase 2 Dexedrine;Placebo
39 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
40 Effects of Tolcapone on Frontotemporal Dementia Unknown status NCT00604591 Phase 2 Tolcapone;Placebo
41 Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury Unknown status NCT02018406 Phase 1, Phase 2 Combination injection of EPO and G-CSF;Injection of normal saline
42 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2 Temozolomide
43 Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
44 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
45 Psychosocial Wellbeing Following Stroke Completed NCT01912014 Phase 1, Phase 2
46 Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease Completed NCT00814697 Phase 2
47 A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia Completed NCT00416169 Phase 2 galantamine hydrobromide
48 Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Completed NCT01056965 Phase 2 davunetide (AL-108, NAP);Placebo nasal spray
49 Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
50 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG

Search NIH Clinical Center for Aphasia

Genetic Tests for Aphasia

Genetic tests related to Aphasia:

# Genetic test Affiliating Genes
1 Aphasia 29

Anatomical Context for Aphasia

MalaCards organs/tissues related to Aphasia:

Brain, Testes, Cortex, Bone, Temporal Lobe, Eye, Prefrontal Cortex

Publications for Aphasia

Articles related to Aphasia:

(show top 50) (show all 1107)
# Title Authors Year
Exploring the efficacy of melodic intonation therapy with Broca's aphasia in Arabic. ( 29943587 )
Sentence composition ability in two patients with non-fluent/agrammatic variant primary progressive aphasia. ( 29409157 )
Treatment for Lexical Retrieval Impairments in Primary Progressive Aphasia: A Research Update with Implications for Clinical Practice. ( 29933491 )
[18F]AV-1451 tau-PET and primary progressive aphasia. ( 29451323 )
Attention control comparisons with SLT for people with aphasia following stroke: methodological concerns raised following a systematic review. ( 29911416 )
Words fail: Lesion-symptom mapping of errors of omission in post-stroke aphasia. ( 29411521 )
Malignant atrophic papulosis with motor aphasia and intestinal perforation: A case report and review of published works. ( 29516548 )
Repetitive sessions of tDCS to improve naming in post-stroke aphasia: Insights from an individual patient data (IPD) meta-analysis. ( 29439369 )
GRIN2A mutations in epilepsy-aphasia spectrum disorders. ( 29056244 )
Pre-articulatory electrical activity associated with correct naming in individuals with aphasia. ( 29421267 )
Tau Uptake in Agrammatic Primary Progressive Aphasia with and without Apraxia of Speech. ( 29935044 )
Cognitive functioning in chronic post-stroke aphasia. ( 29432034 )
Episodic and working memory function in Primary Progressive Aphasia: A meta-analysis. ( 29928907 )
Are there prototypical associations between time frames and aspectual values? Evidence from Greek aphasia and healthy ageing. ( 29939796 )
The Impact of Aphasia Camp Participation on Quality of Life: A Primary Progressive Aphasia Perspective. ( 29933493 )
Proform-Antecedent Linking in Individuals with Agrammatic Aphasia: A Test of the Intervener Hypothesis. ( 29422720 )
Long-Term maintenance of anomia treatment effects in primary progressive aphasia. ( 29380657 )
A Life Participation Approach to Primary Progressive Aphasia Intervention. ( 29933494 )
Rate and rhythm control strategies for apraxia of speech in nonfluent primary progressive aphasia. ( 29682238 )
The role of language proficiency and linguistic distance in cross-linguistic treatment effects in aphasia. ( 29969313 )
Primary progressive aphasia: a clinical approach. ( 29392464 )
Anatomy of aphasia revisited. ( 29360947 )
Molecular neuroimaging in primary progressive aphasia with predominant agraphia. ( 29569990 )
Development, Cross-Cultural Adaptation, and Psychometric Characteristics of the Persian Progressive Aphasia Language Scale in Patients With Primary Progressive Aphasia: A Pilot Study. ( 29942438 )
Barriers and facilitators to meeting aphasia guideline recommendations: what factors influence speech pathologists' practice? ( 29376450 )
Developmental conduction aphasia after neonatal stroke. ( 29572915 )
Atypical Kawasaki Disease Presenting with Hemiparesis and Aphasia: A Case Report. ( 29398757 )
Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. ( 29254097 )
Person-Centered Approaches to Communication Participation and Engagement for Individuals with Primary Progressive Aphasia and Dementia. ( 29933486 )
Error Consistency in Acquired Apraxia of Speech With Aphasia: Effects of the Analysis Unit. ( 29392281 )
Parkinsonism is associated with altered primary motor cortex plasticity in frontotemporal dementia-primary progressive aphasia variant. ( 29909180 )
Transient aphasia after right-unilateral ultrabrief electroconvulsive therapy: A case report. ( 29945792 )
A quick aphasia battery for efficient, reliable, and multidimensional assessment of language function. ( 29425241 )
Assessment of Individuals with Primary Progressive Aphasia. ( 29933490 )
Integration of speech and gesture in aphasia. ( 29411476 )
Multimodal Communication in Aphasia: Perception and Production of Co-speech Gestures During Face-to-Face Conversation. ( 29962942 )
Distinct [<sup>18</sup>F]THK5351 binding patterns in primary progressive aphasia variants. ( 29946950 )
Further Evidence of the Positive Influence of Repetitive Transcranial Magnetic Stimulation on Speech and Language in Patients with Aphasia after Stroke: Results from a Double-Blind Intervention with Sham Condition. ( 29402816 )
Implementing a Standardized Assessment Battery for Aphasia in Acute Care. ( 29359304 )
The Roles of Retrieval Practice Versus Errorless Learning in Strengthening Lexical Access in Aphasia. ( 29946697 )
Predicting Recovery in Acute Post-stroke Aphasia. ( 29451321 )
Adult-onset epileptic aphasia. ( 29960970 )
Maximising recovery from aphasia with central and peripheral agraphia: The benefit of sequential treatments. ( 29298550 )
A Computational Investigation of Sources of Variability in Sentence Comprehension Difficulty in Aphasia. ( 29356427 )
Leukoaraiosis is independently associated with naming outcome in poststroke aphasia. ( 29980639 )
A Novel Phenotype in a Previously Described Epilepsy-Aphasia Disorder. ( 29961510 )
The language disorder of prion disease is characteristic of a dynamic aphasia and is rarely an isolated clinical feature. ( 29304167 )
[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. ( 28912300 )
A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia. ( 28182669 )
Ictal conduction aphasia and ictal angular gyrus syndrome as rare manifestations of epilepsy: The importance of ictal testing during video-EEG monitoring. ( 28913167 )

Variations for Aphasia

ClinVar genetic disease variations for Aphasia:

# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(12;14)(q15;q13)mat Translocation Uncertain significance

Expression for Aphasia

Search GEO for disease gene expression data for Aphasia.

Pathways for Aphasia

GO Terms for Aphasia

Cellular components related to Aphasia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 endosome GO:0005768 9.95 APP C9orf72 CHMP2B GRN LRRK2
2 cell surface GO:0009986 9.93 APP GRIN2A L1CAM PRNP PSEN1
3 neuron projection GO:0043005 9.83 APP GRIN2A LRRK2 MAPT PSEN1
4 membrane raft GO:0045121 9.8 APP LRRK2 PRNP PSEN1
5 lysosome GO:0005764 9.8 C9orf72 CHMP2B GRN LRRK2 SNCA
6 neuronal cell body GO:0043025 9.8 APOE L1CAM LRRK2 MAPT PSEN1 SNCA
7 synaptic vesicle GO:0008021 9.76 GRIN2A LRRK2 SNCA
8 terminal bouton GO:0043195 9.7 APP LRRK2 SNCA
9 dendrite GO:0030425 9.7 APOE C9orf72 L1CAM LRRK2 MAPT PRNP
10 rough endoplasmic reticulum GO:0005791 9.69 APP PSEN1 SNCA
11 postsynapse GO:0098794 9.65 LRRK2 PRNP SNCA
12 smooth endoplasmic reticulum GO:0005790 9.62 APP PSEN1
13 axonal growth cone GO:0044295 9.61 C9orf72 L1CAM
14 nuclear outer membrane GO:0005640 9.61 PSEN1 SNCA
15 amyloid-beta complex GO:0106003 9.57 APOE PRNP
16 ciliary rootlet GO:0035253 9.56 APP PSEN1
17 inclusion body GO:0016234 9.54 LRRK2 PRNP SNCA
18 axon GO:0030424 9.5 APP C9orf72 L1CAM LRRK2 MAPT PSEN1
19 main axon GO:0044304 9.43 APP C9orf72 MAPT
20 growth cone GO:0030426 9.17 APP C9orf72 L1CAM LRRK2 MAPT PSEN1
21 membrane GO:0016020 10.37 APOE APP C9orf72 CHMP2B GRIN2A L1CAM
22 plasma membrane GO:0005886 10.2 APOE APP CHMP2B GRIN2A L1CAM LRRK2
23 endoplasmic reticulum GO:0005783 10.08 APOE GRIN2A GRN LRRK2 PRNP PSEN1
24 Golgi apparatus GO:0005794 10.05 APOE APP LRRK2 PRNP PSEN1 SNCA

Biological processes related to Aphasia according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.9 APP LRRK2 PSEN1
2 neuron projection development GO:0031175 9.88 APP L1CAM MAPT
3 cellular protein metabolic process GO:0044267 9.88 APOE APP PSEN1 SNCA
4 negative regulation of neuron apoptotic process GO:0043524 9.87 APOE PSEN1 SNCA
5 autophagy GO:0006914 9.85 C9orf72 CHMP2B LRRK2 PSEN1
6 excitatory postsynaptic potential GO:0060079 9.81 GRIN2A LRRK2 SNCA
7 memory GO:0007613 9.81 GRIN2A MAPT PSEN1
8 forebrain development GO:0030900 9.79 APP FOXP2 PSEN1
9 learning or memory GO:0007611 9.78 APP GRIN2A PRNP PSEN1
10 regulation of autophagy GO:0010506 9.77 C9orf72 LRRK2 MAPT
11 positive regulation of protein binding GO:0032092 9.77 APP LRRK2 PSEN1
12 response to oxidative stress GO:0006979 9.77 APOE APP LRRK2 PRNP PSEN1
13 negative regulation of neuron death GO:1901215 9.75 APOE LRRK2 SNCA
14 regulation of synaptic plasticity GO:0048167 9.74 GRIN2A MAPT PSEN1
15 regulation of synaptic transmission, glutamatergic GO:0051966 9.72 LRRK2 PSEN1
16 cellular response to copper ion GO:0071280 9.72 PRNP SNCA
17 positive regulation of dendritic spine development GO:0060999 9.72 APOE PSEN1
18 positive regulation of endocytosis GO:0045807 9.71 APOE SNCA
19 ionotropic glutamate receptor signaling pathway GO:0035235 9.71 APP GRIN2A
20 regulation of long-term neuronal synaptic plasticity GO:0048169 9.71 APP SNCA
21 regulation of protein binding GO:0043393 9.71 APP PSEN1
22 response to lead ion GO:0010288 9.71 APP MAPT
23 regulation of neuronal synaptic plasticity GO:0048168 9.7 APOE SNCA
24 regulation of neuron death GO:1901214 9.7 LRRK2 SNCA
25 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.69 APP PRNP
26 positive regulation of long-term synaptic potentiation GO:1900273 9.69 APP GRIN2A
27 cellular copper ion homeostasis GO:0006878 9.69 APP PRNP
28 positive regulation of neuron death GO:1901216 9.69 MAPT PRNP SNCA
29 microglial cell activation GO:0001774 9.68 MAPT SNCA
30 locomotion GO:0040011 9.68 GRIN2A PSEN1
31 dopamine metabolic process GO:0042417 9.68 GRIN2A SNCA
32 axon development GO:0061564 9.68 L1CAM MAPT
33 stress granule assembly GO:0034063 9.67 C9orf72 MAPT
34 locomotory exploration behavior GO:0035641 9.67 APOE LRRK2
35 positive regulation of receptor recycling GO:0001921 9.67 PSEN1 SNCA
36 supramolecular fiber organization GO:0097435 9.66 MAPT SNCA
37 negative regulation of protein processing GO:0010955 9.66 LRRK2 PRNP
38 positive regulation of protein import into nucleus, translocation GO:0033160 9.65 LRRK2 PSEN1
39 amyloid precursor protein metabolic process GO:0042982 9.65 APOE PSEN1
40 amyloid fibril formation GO:1990000 9.65 APP MAPT
41 negative regulation of amyloid-beta formation GO:1902430 9.64 APOE PRNP
42 intracellular distribution of mitochondria GO:0048312 9.63 LRRK2 MAPT
43 negative regulation of long-term synaptic potentiation GO:1900272 9.63 APOE APP PRNP
44 regulation of mitochondrial fission GO:0090140 9.62 LRRK2 MAPT
45 regulation of locomotion GO:0040012 9.62 LRRK2 SNCA
46 positive regulation of microglial cell activation GO:1903980 9.61 APP LRRK2
47 astrocyte activation GO:0048143 9.61 APP MAPT PSEN1
48 modulation of age-related behavioral decline GO:0090647 9.58 APP PRNP PSEN1
49 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.56 APP PSEN1
50 cellular response to amyloid-beta GO:1904646 9.56 APP GRIN2A PRNP PSEN1

Molecular functions related to Aphasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.62 LRRK2 MAPT PRNP SNCA
2 tau protein binding GO:0048156 9.37 APOE SNCA
3 lipoprotein particle binding GO:0071813 9.26 APOE MAPT
4 identical protein binding GO:0042802 9.17 APOE APP FOXP2 LRRK2 MAPT PRNP
5 cuprous ion binding GO:1903136 9.16 PRNP SNCA
6 tubulin binding GO:0015631 9.13 LRRK2 MAPT PRNP
7 protein binding GO:0005515 10.22 APOE APP C9orf72 CHMP2B FOXP2 GRIN2A

Sources for Aphasia

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....